Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

ASH 2024

Lymphoma

Real-world data demonstrate high efficacy of second-line axi-cel in patients with relapsed/refractory large B-cell lymphoma

ASH 2024

Lymphoma

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

SPECIAL REPORT

Lymphoma

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

Lymphoma

Updated Insights from Matching-Adjusted Indirect Comparisons of Two CAR T-cell Therapies in Second-Line Treatment of R/R LBCL

ASH 2024

Lymphoma

Improved management of CRS and ICANS in patients with R/R LBCL treated with axi-cel in clinical practice

SPECIAL REPORT

Breast Cancer

Results of TRODELVY^® real-world data

ASH 2024

Lymphoma

ALYCANTE: Stability or improvement in health-related quality of life three months after infusion of axi-cel in patients with R/R LBCL ineligible for ASCT

Further Publications

Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

Eur J Cancer

Mortier L, Blom A, van Hille B, Samimi M, Luciani L, Cahuzac C, Robert C, Quereux G, Maubec E, Miotti H, Maillard C, Aubin F, Lenormand C, Solbes MN, Joly P, Kachaner I, Lebbé C, Dutriaux C, Saiag P

doi: 10.1016/j.ejca.2024.114261

Related content

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

Real-world data demonstrate high efficacy of second-line axi-cel in patients with relapsed/refractory large B-cell lymphoma

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

Real-World Comparison of YESCARTA® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

Updated Insights from Matching-Adjusted Indirect Comparisons of Two CAR T-cell Therapies in Second-Line Treatment of R/R LBCL

Improved management of CRS and ICANS in patients with R/R LBCL treated with axi-cel in clinical practice

Results of TRODELVY® real-world data

ALYCANTE: Stability or improvement in health-related quality of life three months after infusion of axi-cel in patients with R/R LBCL ineligible for ASCT

Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

Results of TRODELVY^® real-world data